Cosmos Health forecasts $15 million U.S. sales
- Cosmos Health expects approximately $15 million in U.S. direct-to-consumer revenue for Q4 2026, supported by expanded marketing activity and subscription sales.
- The company forecasts approximately $10.5 million in gross profit, equivalent to a 70% gross margin, for its U.S. online business.
- Active U.S. subscriptions reportedly reached 8,940 on October 19, up 42% from October 14, with management targeting more than 40,000 by year-end.
Cosmos Health (NASDAQ:COSM) forecasts approximately $15 million in fourth-quarter 2026 U.S. direct-to-consumer revenue, with projected gross profit of $10.5 million.
The forecast represents a 70% gross margin for its U.S. online business, compared with roughly 8% company-wide GAAP gross margin in Q2.
Cosmos expects $8.2 million from new subscribers' first orders, $3.3 million from subscription renewals and $3.5 million from one-time purchases.
Active U.S. subscriptions reportedly increased 42% to 8,940 by October 19, compared with 6,287 five days earlier.
The company targets more than 40,000 active U.S. subscriptions and daily sales exceeding $200,000 by year-end, although neither outcome is guaranteed.
Cosmos previously reported preliminary nine-month revenue of $54.3 million and reaffirmed its forecast for full-year revenue exceeding $90 million.
The healthcare company operates pharmaceutical manufacturing and distribution businesses alongside proprietary nutraceutical brands, including Sky Premium Life and Mediterranation.
